Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CETP | P11597 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | THRB | P10828 | 3/20 | 0.67 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.65 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419171 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL6410388 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL10025150 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL12451652 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL6410392 | 1.00 | MAPT (0.74) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL16216319 | 0.95 | MAPT (0.65) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL18069580 | 0.91 | MAPT (0.69) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL15385494 | 0.89 | TP53 (0.57) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL15385493 | 0.85 | TP53 (0.54) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| Acetyl Ceramide SCHEMBL58536 | 0.85 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003005965-A2 | MODULATORS OF CERAMIDASE AND METHODS OF USE BASED THEREON | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2003-01-23 | — | — | WO | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3448392-B1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | UNIV EMORY (US) | 2026-02-26 | — | — | US | disclosed |
| US-12414961-B2 | Substituted nucleosides and nucleotides for treating viral infections | EMORY UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2025-09-11 | — | — | US | disclosed |
| US-20240180948-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2024-06-06 | — | — | US | disclosed |
| US-20240173345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS | EMORY UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| WO-2016145142-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| EP-3043803-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014124430-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-08-14 | — | — | WO | disclosed |
| EP-2133335-B9 | SPHINGOSINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND SPHINGOMYELINASE INHIBITOR | OTSUKA CHEMICAL CO LTD (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-8093395-B2 | Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-2133335-B1 | SPHINGOSINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND SPHINGOMYELINASE INHIBITOR | OTSUKA CHEMICAL CO LTD (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-20100099881-A1 | SPHINGOSINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND SPHINGOMYELINASE INHIBITOR | OTSUKA CHEMICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2133335-A1 | SPHINGOSINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND SPHINGOMYELINASE INHIBITOR | Otsuka Chemical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | MAPT 2857/4885CYP2D6 3638/4885MAPK1 3781/4885 |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | MAPT 2568/4885CYP2D6 1619/4885MAPK1 2964/4885 |
| US-20100099881-A1 | SPHINGOSINE COMPOUND, METHOD FOR PRODUCING THE SAME, AND SPHINGOMYELINASE INHIBITOR | SGPL1, SMPD1, SPHK1 | MAPT 4201/4885CYP2D6 3105/4885MAPK1 1655/4885 |
| US-20260053838-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDES AND NUCLEOSIDES FOR TREATING VIRAL INFECTIONS | DCTD, RNMT, NSUN2 | MAPT 4607/4885CYP2D6 546/4885MAPK1 3205/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | MAPT 3771/4885CYP2D6 2487/4885MAPK1 3370/4885 |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | NTPCR, TYMP, MTAP | MAPT 3165/4885CYP2D6 4319/4885MAPK1 3515/4885 |
| US-20240173345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS | PNP, NTPCR, TYMP | MAPT 2346/4885CYP2D6 2414/4885MAPK1 4320/4885 |
| US-20240180948-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | MAPT 2180/4885CYP2D6 2913/4885MAPK1 2139/4885 |
| US-12414961-B2 | Substituted nucleosides and nucleotides for treating viral infections | PNP, NTPCR, TYMP | MAPT 3274/4885CYP2D6 1574/4885MAPK1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.